Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
6.397 EUR
82.53 M EUR
221.81 M EUR
11.31 M
About Basilea Pharmaceutica AG
Sector
Industry
CEO
David Veitch
Website
Headquarters
Allschwil
Founded
2000
ISIN
CH0011432447
FIGI
BBG004MWYV37
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. Its products include antifungals and antibiotics. The company was founded on October 17, 2000, and is headquartered in Allschwil, Switzerland.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on TRADEGATE exchange Basilea Pharmaceutica AG stocks are traded under the ticker PK5.
We've gathered analysts' opinions on Basilea Pharmaceutica AG future price: according to them, PK5 price has a max estimate of 106.78 EUR and a min estimate of 59.48 EUR. Watch PK5 chart and read a more detailed Basilea Pharmaceutica AG stock forecast: see what analysts think of Basilea Pharmaceutica AG and suggest that you do with its stocks.
Yes, you can track Basilea Pharmaceutica AG financials in yearly and quarterly reports right on TradingView.
Basilea Pharmaceutica AG is going to release the next earnings report on Feb 17, 2026. Keep track of upcoming events with our Earnings Calendar.
PK5 earnings for the last half-year are 1.35 EUR per share, whereas the estimation was 2.17 EUR, resulting in a −37.93% surprise. The estimated earnings for the next half-year are 3.28 EUR per share. See more details about Basilea Pharmaceutica AG earnings.
Basilea Pharmaceutica AG revenue for the last half-year amounts to 111.28 M EUR, despite the estimated figure of 105.07 M EUR. In the next half-year revenue is expected to reach 126.26 M EUR.
PK5 net income for the last half-year is 16.91 M EUR, while the previous report showed 60.47 M EUR of net income which accounts for −72.04% change. Track more Basilea Pharmaceutica AG financial stats to get the full picture.
No, PK5 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 22, 2025, the company has 164 employees. See our rating of the largest employees — is Basilea Pharmaceutica AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Basilea Pharmaceutica AG EBITDA is 85.20 M EUR, and current EBITDA margin is 31.03%. See more stats in Basilea Pharmaceutica AG financial statements.
Like other stocks, PK5 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Basilea Pharmaceutica AG stock right from TradingView charts — choose your broker and connect to your account.